


# Stabilis



## Esmolol hydrochloride



Noms commerciaux

Brevibloc	Allemagne, Autriche, Belgique, Canada, Danemark, Egypte, Emirats Arabes Unis, Equateur, Espagne, Etats Unis d'Amérique, Finlande, France, Grande Bretagne, Grèce, Hongrie, Iran, Irlande, Italie, Mexique, Norvège, Nouvelle Zélande, Portugal, Suède, Suisse, Turquie
Cardesmo	Inde
Crevimol	Mexique
Esmocard	Allemagne, Belgique, Espagne, Inde, Suède
Esmolol	Argentine, Chili, Etats Unis d'Amérique, Iran, Suisse
Esocard	Inde, Malaisie
Nevopax	Mexique
Solmosol	Mexique



### Stabilité des solutions

		10 mg/ml	23°C-27°C		7			204
		10 mg/ml	5°C		7			204
	RL	10 mg/ml	23°C-27°C		7			204
	RL	10 mg/ml	5°C		7			204
		10 mg/ml	23°C-27°C		7			204
		10 mg/ml	5°C		7			204
PVC		10 mg/ml	23°C-27°C		7			204
PVC		10 mg/ml	5°C		7			204
PVC	RL	10 mg/ml	23°C-27°C		7			204
PVC	RL	10 mg/ml	5°C		7			204
PVC		10 mg/ml	23°C-27°C		7			204

		10 mg/ml	5°C		7			204
--	--	----------	-----	--	---	--	--	-----



### Stabilité en mélange

		5 mg/ml	15°C-30°C		Morphine sulfate : 7,5 mg/ml	8		8
		5 mg/ml	15°C-30°C		Fentanyl citrate : 25 µg/ml	8		8
		10 mg/ml	15-30°C		Nitroprusside sodium : 0,2 mg/ml	24		363



### Facteur influençant la stabilité

	NaHCO <sub>3</sub>			204
	NaHCO <sub>3</sub>			3607



### Compatibilités

	Esmolol hydrochloride : 10 mg/ml Amikacin sulfate : 5 mg/ml
	384
	Esmolol hydrochloride : 6 mg/ml Aminophylline : 1 mg/ml
	174
	Esmolol hydrochloride : 10 mg/ml Aminophylline : 1 mg/ml
	384
	Esmolol hydrochloride : 40 mg/ml Amiodarone hydrochloride : 4.8 mg/ml
	295
	Esmolol hydrochloride : 10 mg/ml Amiodarone hydrochloride : 15 mg/ml
	3823
	Esmolol hydrochloride : 10 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml
	3824
	Esmolol hydrochloride : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml
	921
	Esmolol hydrochloride : 10 mg/ml Argatroban : 1 mg/ml
	3764
	Esmolol hydrochloride : 10 mg/ml Atracurium besylate : 0.5 mg/ml
	402
	Esmolol hydrochloride : 10 mg/ml Bivalirudin : 5 mg/ml
	1713
	Esmolol hydrochloride : 6 mg/ml Bretylium tosilate : 1 mg/ml
	174
	Esmolol hydrochloride : 10 mg/ml Butorphanol tartrate : 0,04 mg/ml
	384
	Esmolol hydrochloride : 10 mg/ml Caffeine : 10 mg/ml
	3964








	Esmolol hydrochloride : 10 mg/ml Calcium chloride : 20 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Cefazolin sodium : 10 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Cefepime dihydrochloride : 40 mg/ml		3879
	Esmolol hydrochloride : 25 mg/ml Cefmetazole sodium : 100 mg/ml		93
	Esmolol hydrochloride : 10 mg/ml Cefoperazone sodium : 10 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Ceftazidime : 10 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Ceftizoxime sodium : 10 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	 	3828
	Esmolol hydrochloride : 10 mg/ml Chloramphenicol sodium succinate : 10 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Cimetidine hydrochloride : 6 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Ciprofloxacin lactate : 2 mg/ml		3879
	Esmolol hydrochloride : 10 mg/ml Cisatracurium besylate : 2 mg/ml		3879
	Esmolol hydrochloride : 10 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Esmolol hydrochloride : 10 mg/ml Cisatracurium besylate : 5 mg/ml		3823
	Esmolol hydrochloride : 10 mg/ml Clindamycin phosphate : 9 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Esmolol hydrochloride : 10 mg/ml Co-trimoxazole : 0.64/3.2 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Esmolol hydrochloride Diazepam		3607
	Esmolol hydrochloride : 10 mg/ml Diltiazem hydrochloride : 1 mg/ml		524
	Esmolol hydrochloride : 10 mg/ml Dopamine hydrochloride : 1,6 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Doripenem : 4.5 mg/ml		3879
	Esmolol hydrochloride : 10 mg/ml Doripenem : 5 mg/ml	 	2262
	Esmolol hydrochloride : 10 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Esmolol hydrochloride : 10 mg/ml Epinephrine hydrochloride : 128 µg/ml		3879
	Esmolol hydrochloride : 10 mg/ml Eravacycline : 0,6 mg/ml		4434

		Esmolol hydrochloride : 10 mg/ml Erythromycin lactobionate : 5 mg/ml		384
		Esmolol hydrochloride : 10 mg/ml Esomeprazole sodium : 0,8 mg/ml		3879
		Esmolol hydrochloride : 10 mg/ml Famotidine : 0.2 mg/ml		398
		Esmolol hydrochloride : 10 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Esmolol hydrochloride : 5 mg/ml Fentanyl citrate : 25 µg/ml		8
		Esmolol hydrochloride : 5 mg/ml Fentanyl citrate : 25 µg/ml		8
		Esmolol hydrochloride : 10 mg/ml Fosfomycin : 30 mg/ml	 	4055
		Esmolol hydrochloride : 10 mg/ml Furosemide : 10 mg/ml	 	523
		Esmolol hydrochloride : 20 mg/ml Furosemide : 1 mg/ml		4570
		Esmolol hydrochloride Furosemide		3607
		Esmolol hydrochloride : 10 mg/ml Furosemide : 10 mg/ml		3823
		Esmolol hydrochloride : 10 mg/ml Furosemide : 10 mg/ml		3210
		Esmolol hydrochloride : 10 mg/ml Furosemide : 10 mg/ml		3664
		Esmolol hydrochloride : 10 mg/ml Gentamicin sulfate : 0,8 mg/ml		384
		Esmolol hydrochloride : 6 mg/ml Heparin sodium : 50 UI/ml		174
		Esmolol hydrochloride : 10 mg/ml Heparin sodium : 40 UI/ml		384
		Esmolol hydrochloride : 10 mg/ml Heparin sodium : 500 UI/ml		3823
		Esmolol hydrochloride : 10 mg/ml Hetastarch : 60 mg/ml		1721
		Esmolol hydrochloride : 10 mg/ml Human albumin : 250 mg/ml		3879
		Esmolol hydrochloride : 10 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		384
		Esmolol hydrochloride : 10 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		3879
		Esmolol hydrochloride : 10 mg/ml Ibuprofen lysinate : 4 mg/ml		3879
		Esmolol hydrochloride : 10 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml	 	4433
		Esmolol hydrochloride : 40 mg/ml Insulin : 1 UI/ml		295
		Esmolol hydrochloride : 10 mg/ml Isavuconazonium sulfate : 1.5 mg/ml	 	3829
		Esmolol hydrochloride : 10 mg/ml Ketamine hydrochloride : 50 mg/ml		4389

	Esmolol hydrochloride : 40 mg/ml Labetalol hydrochloride : 5 mg/ml		295	
	Esmolol hydrochloride : 10 mg/ml Labetalol hydrochloride : 4 mg/ml		3823	
		Esmolol hydrochloride : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
	Esmolol hydrochloride : 10 mg/ml Levofloxacin : 5 mg/ml		3879	
	Esmolol hydrochloride : 10 mg/ml Levothyroxine : 0.4 µg/ml		3879	
	Esmolol hydrochloride : 10 mg/ml Linezolid : 2 mg/ml		1925	
	Esmolol hydrochloride : 10 mg/ml Magnesium sulfate : 10 mg/ml		384	
	Esmolol hydrochloride : 10 mg/ml Meropenem : 20 mg/ml		3879	
	Esmolol hydrochloride : 10 mg/ml Meropenem : 50 mg/ml		4319	
	Esmolol hydrochloride : 10 mg/ml Metronidazole : 5 mg/ml		384	
	Esmolol hydrochloride : 10 mg/ml Micafungin : 1.5 mg/ml		2108	
	Esmolol hydrochloride : 10 mg/ml Midazolam hydrochloride : 2.1 mg/ml		3823	
	Esmolol hydrochloride : 40 mg/ml Midazolam hydrochloride : 1 mg/ml		295	
	Esmolol hydrochloride : 10 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408	
	Esmolol hydrochloride : 40 mg/ml Norepinephrine bitartrate : 0.064 mg/ml		295	
		Esmolol hydrochloride		3607
	Esmolol hydrochloride : 10 mg/ml Milrinone lactate : 1 mg/ml		4389	
	Esmolol hydrochloride : 5 mg/ml Morphine sulfate : 7,5 mg/ml		8	
	Esmolol hydrochloride : 5 mg/ml Morphine sulfate : 7,5 mg/ml		8	
	Esmolol hydrochloride : 10 mg/ml Nafcillin sodium : 10 mg/ml		384	
	Esmolol hydrochloride : 10 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	 	1490	
	Esmolol hydrochloride : 10 mg/ml Nitroglycerin : 0.2 mg/ml	 	3823	
	Esmolol hydrochloride : 10 mg/ml Nitroprusside sodium : 0,2 mg/ml		363	
	Esmolol hydrochloride : 10 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		3879	
	Esmolol hydrochloride : 10 mg/ml Pancuronium bromide : 0.05 mg/ml		402	
		Esmolol hydrochloride : < 2 mg/ml Pantoprazole sodium : < 0.12 mg/ml		1902

		Esmolol hydrochloride : > 2 mg/ml Pantoprazole sodium : > 0.12 mg/ml		1902
		Esmolol hydrochloride : 10 mg/ml Paracetamol : 10 mg/ml		3879
		Esmolol hydrochloride : 10 mg/ml Paracetamol : 10 mg/ml		4742
		Esmolol hydrochloride : 10 mg/ml Penicillin G potassium : 0,05 MUI/ml		384
		Esmolol hydrochloride : 10 mg/ml Phenytoin sodium : 1 mg/ml		384
		Esmolol hydrochloride : 10 mg/ml Piperacillin sodium : 30 mg/ml		384
		Esmolol hydrochloride : 10 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Esmolol hydrochloride : 10 mg/ml Polymyxine B : 0,005 mg/ml		384
		Esmolol hydrochloride : 10 mg/ml Potassium phosphate : 0,44 mmol/ml		384
		Esmolol hydrochloride : 6 mg/ml Procainamide hydrochloride : 4 mg/ml		174
		Esmolol hydrochloride : 10 mg/ml Propofol : 10 mg/ml		300
		Esmolol hydrochloride : 10 mg/ml Ranitidine hydrochloride : 0,5 mg/ml		384
		Esmolol hydrochloride : 10 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Esmolol hydrochloride : 10 mg/ml	RL	4603
		Esmolol hydrochloride : 10 mg/ml Potassium chloride : 0,4 mEq/l		384
		Esmolol hydrochloride Sodium bicarbonate		3607
		Esmolol hydrochloride : 10 mg/ml Sodium bicarbonate : 84 mg/ml		3823
		Esmolol hydrochloride Sodium bicarbonate		3466
		Esmolol hydrochloride : 10 mg/ml Streptomycin sulfate : 10 mg/ml		384
		Esmolol hydrochloride : 10 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Esmolol hydrochloride : 10 mg/ml Tacrolimus : 1000 µg/ml		479
		Esmolol hydrochloride : 10 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Esmolol hydrochloride Thiopental sodium		3607
		Esmolol hydrochloride : 10 mg/ml Tirofiban : 250 µg/ml		3823
		Esmolol hydrochloride : 10 mg/ml Tobramycin sulfate : 0.8 mg/ml		384
		Esmolol hydrochloride : 10 mg/ml Urapidil : 5 mg/ml		3823



	Esmolol hydrochloride : 10 mg/ml Vancomycin hydrochloride : 5 mg/ml		384
	Esmolol hydrochloride : 10 mg/ml Vecuronium bromide : 0.1 mg/ml		402
 	Esmolol hydrochloride : 10 mg/ml Warfarin sodium : 2 mg/ml		315



## Voie d'administration



## Bibliographie

	Type	Source
8	Revue	Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER. Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 368-371.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
174	Revue	Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm 1990 ; 47: 1567-1571.
204	Revue	Baaske DM, Dyskstra SD, Wagenknecht DM, Karnatz NN. Stability of esmolol hydrochloride in intravenous solutions. Am J Hosp Pharm 1994 ; 51: 2693-2696.
295	Revue	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
363	Revue	Karnatz NN, Wong J, Baaske DM, Johnson JH, Speicher ER, Herbranson DE. Stability of esmolol hydrochloride and sodium nitroprussiate in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 101-104.

384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
523	Revue	Thompson DF, Thompson GD. Visual compatibility of esmolol hydrochloride and furosemide in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm 1987 ; 44: 2740.
524	Revue	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.



2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3210	Revue	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3466	Revue	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3607	Laboratoire	Esmolol hydrochloride for injection - Summary of Product Characteristics AOP Orphan Pharmaceuticals AG 2013
3664	Revue	Zhao B, Sun W. Incompatibility of esmolol hydrochloride and furosemide in a central venous access port Am J Health-Syst Pharm 2014 ; 71:901-902.
3764	Revue	Jakimczuk P.J, Churchwell M.D, Howard M.S, Mauro V.F, Alexander K.S, Boddu S.H.S. Compatibility of argatroban injection with select antiarrhythmic drugs Am J Health-Syst Pharm 2014 2014; 71: 1831-1832.
3823	Revue	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs  Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Revue	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4570	Revue	Greenhill K, Hornsby E, Gorman G. Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients. Pharmaceuticals 2019
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



# Dictionnaire

 Béta-bloquant	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 Lumière
 Jour	 A l'abri de la lumière
<b>RL</b> Ringer lactate	 Chlorure de sodium 0,45%
 Polyvinyl chlorure	 Stabilité en mélange
 Solvant	 Molécule
 Heure	 Non précisé
 Glucose 5%	 Facteur influençant la stabilité
 Provoque	 Diminution de la stabilité
 NaHCO <sub>3</sub>	 Dégradation
 Compatibilités	 Compatible
 Précipitation immédiate	 Incompatible
 Aucun	 Chlorure de sodium 0,9%
 Eau pour préparation injectable	 Incompatibilité non précisée
 Changement de couleur	 Solvant spécifique
 Turbidité immédiate	 Voie d'administration
 Intraveineuse	 Perfusion intraveineuse
 Bibliographie	 Dictionnaire